跳至主要内容
临床试验/EUCTR2018-004119-36-NO
EUCTR2018-004119-36-NO进行中(未招募)1 期

Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.

Oslo University Hospital0 个研究点目标入组 90 人开始时间: 2019年6月24日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma)
  • Planned for radical chemoradiotherapy
  • Included in the MIMB-protocol
  • Over 18 years
  • Speaks and understands Norwegian
  • Cervical tumor available for biopsy by gynecological examination
  • Able to receive weekly cisplatin
  • Able to take oral medication
  • Ability to understand and willing to sign a written informed consent
  • Willing to undergo biopsies of cervical tumor
  • Willing to be included in the Embrace 2- protocol if randomized to the control group
  • Negative pregnancy test in women with childbearing potential
  • Normal bone marrow and organ function = 14 days before inclusion
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 45

排除标准

  • Evidence of distant metastasis. Suspicious paraaortic lymphnodes below the renal wessel is allowed if they are covered by the radiation field
  • Patients who have received other cancer treatments for their cervical cancer
  • Patients who receive other experimental drugs
  • Known diabetes mellitus
  • Currently taking Metformin or any other antidiabetic drugs (sulfonylureas, thiazolidinediones, insulin)
  • History of allergic reaction attributed to compounds of similar chemical or biologic composition to metformin
  • Any condition associated with increased risk of metformin- induced lactic acidosis (congestive heart failure defined as New York Heart Association (NYHA) class III or IV functional status, history of acidosis of any kind)
  • Uncontrolled intercurrent somatic illness including, but not limited to, ongoing or active serious infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction within 6 months and cerebrovascular disease with previous stroke
  • Psychiatric illness /social situations limiting study compliance
  • Prior radiotherapy to the pelvis
  • Already on medication with increased risk of lactic acidosis
  • Patients who are pregnant or breastfeeding are excluded due to risk of teratogenic and abortifacient effects of radiotherapy and cisplatin, and the potential risk of adverse effect of nursing infants
  • Patients with other invasive malignancies except non-melanoma skin cancers
  • Known HIV-positive patients on antiretroviral therapy
  • Known conditions limiting absorption of study drug (bowel obstruction, malabsorption syndromes)
  • Patients taking the drug disulfiram (antabus)

研究者

发起方
Oslo University Hospital

相似试验